The UK is dubbed the ‘addiction capital of Europe’ with drug and alcohol-related problems costing society over £36 billion per year. Used by members of the public, the legal profession, local authorities and employers – and with the support of the Courts – Barry Sheehan discusses the growing demand for drug and alcohol testing in the UK.
Currently, the testing landscape is highly competitive and fragmented, with only a few key players dominating market share. In a market primed for consolidation with attractive growth prospects, increasing demand and limited supply, Barry argues that there is a compelling rationale for both strategic acquirers and Private Equity investors to further explore the M&A and expansion prospects in the sector.
Read Barry’s comments on the growth prospects of the drug and alcohol testing market in European Pharmaceutical Review here.